Xilio Therapeutics is a biotechnology company that develops tumor-activated immuno-oncology therapies.
Xilio Therapeutics has raised $40.0M in total funding. The most recent round was Post-IPO Equity. The last funding was announced in February 2026.
Xilio Therapeutics's investors include RA Capital Management, Gilead Sciences, Perceptive Advisors, OrbiMed, Bain Capital Life Sciences.
Xilio Therapeutics is headquartered in Waltham, United States.
Xilio Therapeutics is a biotechnology company that develops tumor-activated immuno-oncology therapies.
Xilio Therapeutics is at the Post-IPO Equity stage.
Free to use in articles, research, and reference works. Stable URL — will not change. Data on this page last updated .
"Xilio Therapeutics — Funding & Investors." VCBacked, February 11, 2026, https://www.vcbacked.co/company/xilio-therapeutics. Accessed July 19, 2026.
VCBacked. (2026). Xilio Therapeutics — Funding & Investors. Retrieved July 19, 2026, from https://www.vcbacked.co/company/xilio-therapeutics
{{cite web |title=Xilio Therapeutics — Funding & Investors |url=https://www.vcbacked.co/company/xilio-therapeutics |website=VCBacked |access-date=July 19, 2026}}Profile data sourced and verified per the VCbacked methodology · Last funding round dated